Key result
Amiodarone therapy for life-threatening ventricular tachyarrhythmias was associated with a mean annual death rate of 6.2% and an annual withdrawal rate of 8%.
Why the study?
Does amiodarone therapy improve outcomes in patients with life-threatening ventricular tachyarrhythmias?
Does amiodarone therapy improve outcomes in patients with life-threatening ventricular tachyarrhythmias?
Answers are grounded in this paper and cite their sources.
Amiodarone therapy for life-threatening ventricular tachyarrhythmias is associated with a 6.2% annual death rate, though high-risk patients (low LVEF, persistent VT, prior cardiac arrest) may require additional interventions such as an ICD.
Summary: The present article reviews the experience with amiodarone therapy in life-threatening ventricular tachyarrhythmias. In 13 studies, 1,594 patients were treated with amiodarone in average doses of 300 mg/day. The mean annual death rate was 6.2% the annual withdrawal rate averaged 8%. Risk factors for arrhythmia recurrence despite amiodarone therapy were low left ventricular ejection fraction, inducible ventricular tachycardia by programmed electrical stimulation or persisting ventricular tachycardia on Holter monitoring, and cardiac arrest before the institution of amiodarone therapy. In these patients, additional antiarrhythmic measures such as an automatic implantable cardioverter/defibrillator or other surgical interventions must be considered.
No takes yet. Share an insight, caveat, or question.
D Burckhardt (1992) conducted a review in Life-threatening ventricular tachyarrhythmias (n=1,594). Amiodarone was evaluated on Annual death rate. Amiodarone therapy for life-threatening ventricular tachyarrhythmias was associated with a mean annual death rate of 6.2% and an annual withdrawal rate of 8%.
Synapse has enriched 10 related papers. Consider them for comparative context: